Why the study?
Limited data are available to demonstrate the effectiveness of midodrine in the prevention of intradialysis hypotension in high-risk hemodialysis patients.
Does midodrine dosing frequency affect the incidence of intradialytic hypotension in high-risk hemodialysis patients?
Does midodrine dosing frequency affect the incidence of intradialytic hypotension in high-risk hemodialysis patients?
Daily administration of midodrine may be more effective than thrice-weekly dosing for preventing intradialytic hypotension in high-risk hemodialysis patients.
Limited data on midodrine for IDH prevention warrant caution in high-risk patients; leaves open efficacy pending prospective trials.
Intradialysis hypotension (IDH) is the most common complication during hemodialysis procedure. Midodrine, an oral α-1 adrenergic agonist, is commonly used to prevent IDH. However, limited data is available to demonstrate midodrine effectiveness in prevention of IDH in high-risk hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
Saja et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: